26.08.2010 • News • Allergan • Bausch & Lomb • Bloomberg

Sanofi Won't Go Above $70 per Share for Genzyme

Sanofi-Aventis is not willing to pay more than $70 per share for U.S. biotech Genzyme and may look at alternative targets, Bloomberg reported on Wednesday, citing sources familiar with the matter.

France's Sanofi has offered $69 per share for Genzyme and its board has authorized a bid of up to $70 per share, sources have told press representatives in the past.

According to the Bloomberg report, Sanofi may consider companies such as Bausch & Lomb, Allergan or Celgene if a deal with Genzyme falls through.

Interview

Strategic Response to a Shifting Pharma Landscape

Stability in Motion

Stefan Oelrich, Member of the Board of Management and President Pharmaceuticals, Bayer, discusses navigating external volatility, reshaping its internal structures, and investing in future-ready capabilities to ensure sustainable growth.

Special Issue

Explore the Future of Plastics

Circular Plastics Economy

This special CHEManager issue explores the industry’s pivotal shift towards a more sustainable, circular plastics value chain. Readers will find expert analysis and real-world solutions for today’s most pressing recycling and regulatory challenges.